Oncogene:昆明动物所在 miRNA 调控乳腺癌血管新生研究中取得进展

2018-02-12 佚名 昆明动物研究所

近日,中国科学院昆明动物研究所陈策实课题组在 miRNA 调控乳腺癌血管新生功能与机制研究中取得进展,研究成果以 Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis 为题,在线发表在 Oncogene 上。该研究揭


缺氧条件下 miR-153 表达调控及其靶向 HIF1α/VEGFA 通路模式图

近日,中国科学院昆明动物研究所陈策实课题组在 miRNA 调控乳腺癌血管新生功能与机制研究中取得进展,研究成果以 Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis 为题,在线发表在 Oncogene 上。该研究揭示了受缺氧应激诱导的 miR-153 通过下调 HIF1α/VEGFA 信号通路而抑制乳腺癌的血管新生。

实体瘤的生长依赖于血液为其提供充足的营养和氧气。因肿瘤细胞具有增殖快速且不受调控的特点,在实体瘤内部极易出现缺氧微环境。为应对缺氧压力,肿瘤细胞通过激活 HIF1α/VEGFA 信号通路而促进肿瘤内血管新生,因此通过靶向该信号通路而将肿瘤的发展阻断在血管新生的早期,则能有效抑制实体瘤的生长、侵袭、以及转移。MiR-153 是一个古老且进化保守的 miRNA 分子,在多种类型的肿瘤中扮演着肿瘤抑制因子的角色。前期研究发现米非司酮可以诱导 miR-153,从而抑制 KLF5 转录因子表达来抑制乳腺癌干细胞。但对于 miR-153 在肿瘤中表达调控机制,以及该 miRNA 分子在调控肿瘤细胞活性中的功能和机制尚未完全清楚。

该研究发现 miR-153 通过靶向作用于 HIF1A 癌基因 mRNA 的 3’UTR 而抑制缺氧对乳腺癌细胞中 HIF1α/VEGFA 信号通路的激活,从而阻断肿瘤的血管新生,抑制裸鼠移植瘤的生长。该研究进一步探讨了 miR-153 的表达调控机制,并发现缺氧可通过触发细胞内的内质网应激(ER stress)反应而激活 IRE1α/XBP1 信号通路,被激活的转录因子 XBP1 通过作用于 miR-153 宿主基因 PTPRN 的启动子区域而诱导 PTPRN 和 miR-153 的共同表达。因此,在缺氧的病理生理条件下,肿瘤细胞一方面快速激活 HIF1α/VEGFA 通路而促进肿瘤的血管新生,同时可通过激活内质网应激上调 miR-153,从而实现对 HIF1α/VEGFA 信号通路的负性微调,与其他负性调控因子一起以类似“刹车机制”避免肿瘤细胞内该信号通路的过度激活,维持正常和肿瘤组织的稳态(如图)。在证明 miR-153 抑制乳腺癌干细胞的前期基础上,该工作清楚表明 miR-153 的确是一个强的抑癌基因,可以通过抑制血管新生抑制乳腺癌,miR-153 也许将来可以用于乳腺癌的基因治疗。

陈策实课题组博士梁慧春为文章的第一作者,研究员陈策实和刘蓉为文章共同通讯作者。研究工作得到了中科院战略性先导科技专项、国家自然科学基金以及云南省应用基础研究重点项目的资助。

原始出处:

Huichun Liang, Ji Xiao, Zhongmei Zhou, et al. Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis. Oncogene (2018), doi:10.1038/s41388-017-0089-8.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-10-13 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-03-25 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-15 changjiu

    学习一下谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-14 Homburg
  6. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-14 zsyan
  7. [GetPortalCommentsPageByObjectIdResponse(id=1740391, encodeId=02f81e40391a5, content=<a href='/topic/show?id=5996896e011' target=_blank style='color:#2F92EE;'>#血管新生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89670, encryptionId=5996896e011, topicName=血管新生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=093634755022, createdName=ms1467340776200723, createdTime=Tue Dec 18 09:08:00 CST 2018, time=2018-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048981, encodeId=5133204898142, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Oct 13 19:08:00 CST 2018, time=2018-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930587, encodeId=6549193058e80, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sun Mar 25 14:08:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=288239, encodeId=0729288239b5, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Thu Feb 15 22:25:56 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312338, encodeId=10491312338ac, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558109, encodeId=a8f51558109d0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed Feb 14 04:08:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=287373, encodeId=a8d428e373f1, content=谢谢.我学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4c106013, createdName=Drhzm308, createdTime=Mon Feb 12 13:55:59 CST 2018, time=2018-02-12, status=1, ipAttribution=)]
    2018-02-12 Drhzm308

    谢谢.我学习了

    0

相关资讯

Nat Commun:促进三阴性乳腺癌扩散转移的“核心原因”已确定

克利夫兰诊所的研究人员在《自然通讯》杂志上发表了一项新的干细胞途径,促进一种高度侵袭性的乳腺癌三重阴性乳腺癌得以茁壮成长。

Nat Commun:一种氨基酸水平影响乳腺癌扩散

英国癌症研究会发布的一项新研究显示,天冬酰胺这种氨基酸在乳腺癌扩散过程中扮演重要角色。限制小鼠体内的天冬酰胺水平能降低癌细胞扩散几率,这一发现有助未来给病患提供更好的治疗方案。

Lancet oncol:双重封闭HER2联合环磷酰胺治疗HER2阳性的转移性乳腺癌患者的效果评估

转移性乳腺癌在老年人群中发病率高,死亡率高,但目前我们对乳腺癌老年患者的最佳治疗方式认识远远不足。现研究人员对双重抗HER2治疗联合或不联合计划性化疗治疗HER2阳性的转移性乳腺癌患者的效果进行评估。研究人员在欧洲的8个国家的30个中心进行一多中心的、开放性的随机化临床2期试验,招募60岁及以上的组织学确诊的HER2阳性的转移性乳腺癌患者,且要求既往未对转移灶进行过化疗、预期存活超过12周、体力状

MNT:这些癌症干细产生新癌症治疗方法

三阴性乳腺癌存活率差。然而,一项新研究的结果 - 研究人员发现一种可能促进该疾病的干细胞途径 - 可能会导致新的治疗方法。

一些乳腺癌疗法可能增加心血管疾病风险

美国心脏病协会近日以科学声明形式向乳腺癌患者发出警告:一些化学和放射疗法可能增加心力衰竭等心血管疾病风险,患者在接受治疗前应慎重考虑相关利弊。

JCO:锻炼可降低肥胖乳腺癌幸存者心血管风险

一项最新研究表明,运动可帮助超重和肥胖的乳腺癌幸存者改善逆转综合征。该项研究发表于1月22日的《临床肿瘤学杂志》(Journal Of ClinicalOncology)。